• Declining mortality rates over time |
• Over-estimated treatment effects |
• Suboptimal pre-clinical models |
• Knowledge of pathophysiology is still evolving, making pathophysiologic targets difficult to identify |
• Incorrect treatment targets |
• Heterogeneity of the syndrome |
• Heterogeneity of the patient population |
• Improbability that a single treatment can impact key pathophysiologic processes that influence all-cause mortality |